Patent ID: 11903945
Assignee: CORCEPT THERAPEUTICS INCORPORATED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 6:
7. A method of treating a subject at risk of suffering from antipsychotic-induced weight gain, the method comprising administering to the subject an effective amount of the cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) miricorilant, (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, which has the structure:, while said subject is administered an antipsychotic medication, wherein the subject has not previously been administered an antipsychotic medication, and wherein said treatment is effective to:
reduce the weight gain of a subject over time while taking said antipsychotic medication and said GRM, as compared to average weight gain of subjects administered that antipsychotic medication in the absence of the GRM; or
reduce the increase in blood levels of triglycerides as compared to the average increase in triglyceride levels in the blood of subjects administered said antipsychotic medication; or
reduce the increase in blood levels of liver enzymes alanine aminotransferase (ALT), or aspartate aminotransferase (AST), or both, as compared to the baseline liver enzyme levels in the blood of subjects prior to administration of said antipsychotic medication; or
reduce the increase in plasma insulin level as compared to the average increase in plasma insulin level in subjects administered said antipsychotic medication; or
reduce the increase in insulin resistance (as measured by HOMA-IR or HOMA2-IR) as compared to the average increase in insulin resistance of in subjects administered said antipsychotic medication; or combinations thereof.